BUSINESS
Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
Japanese PI studies still pose a barrier for global companies to develop their medicines in Japan despite the recent regulatory reforms by local authorities, says a senior official of Parexel International. The US CRO hopes to see drug makers tap…
To read the full story
Related Article
- Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





